Show simple item record

dc.contributor.authorJudson, I
dc.date.accessioned2018-06-26T10:56:12Z
dc.date.issued2010-10
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2010, 21 Suppl 7 pp. vii277 - vii280
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1938
dc.identifier.eissn1569-8041
dc.identifier.doi10.1093/annonc/mdq288
dc.description.abstractSoft tissue sarcomas are rare cancers but because of their association with characteristic chromosomal translocations and activating mutations they may be particularly susceptible to molecularly targeted therapies. Gastrointestinal stromal tumour (GIST) became the paradigm for targeted therapy in solid tumours owing to the success of imatinib, which has transformed the prognosis in this disease. Translocation-driven tumours have proved harder to target, but the impact of fusion proteins on gene expression is beginning to be understood and may also reveal new targets for therapy, such as insulin-like growth factor 1 receptor, now that effective inhibitors have been discovered. Angiogenesis inhibition also appears to be a promising area for research in sarcomas and many new targets are emerging at the same time as agents capable of investigating them in the clinic are being developed. It is not unrealistic to hope that targeted therapies will play an increasing role in the management of sarcomas in the near future.
dc.formatPrint
dc.format.extentvii277 - vii280
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectSarcoma
dc.subjectSoft Tissue Neoplasms
dc.subjectGastrointestinal Stromal Tumors
dc.subjectAngiogenesis Inhibitors
dc.subjectSomatomedins
dc.subjectSignal Transduction
dc.subjectTOR Serine-Threonine Kinases
dc.subjectMolecular Targeted Therapy
dc.titleTargeted therapies in soft tissue sarcomas.
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdq288
rioxxterms.licenseref.startdate2010-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.publication-statusPublished
pubs.volume21 Suppl 7
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trialsen_US
dc.contributor.icrauthorJudson, Ianen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record